World Headquarters: 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
Chairman and CEO: Fred Hassan
Number of Employees: approximately 55,000
Net Sales (2007): $12.7 billion
Business operations in more than 140 countries
Largest-selling products: VYTORIN*, ZETIA*, REMICADE, NASONEX
R&D investment (2007): $2.9 billion
Web Site Address: www.schering-plough.com
Stock Exchange Listings: New York Stock Exchange (SGP)
Unlisted Trading: Boston Stock Exchange
Cincinnati Stock Exchange
Midwest Stock Exchange
Pacific Stock Exchange
Philadelphia Stock Exchange
Key Products:
ASMANEX (mometasone furoate)
AVELOX (moxifloxacin)
CAELYX (pegylated liposomal doxorubicin HCI) [marketed internationally only]
CLARINEX (desloratadine)
CLARITIN (loratadine)
FOLLISTIM (follitropin beta)
INTEGRILIN (eptifibatide)
INTRON A (interferon alfa-2b)
NASONEX (mometasone furoate monohydrate)
NOXAFIL (posaconazole)
PEGINTRON (peginterferon alfa-2b)
REMICADE (infliximab) [marketed internationally only]
TEMODAR (temozolomide)
VYTORIN (ezetemibe/simvastatin) (Joint venture with Merck & Co., Inc.)
ZEMURON (rocuronium bromide)
ZETIA (ezetimibe) (Joint venture with Merck & Co., Inc.)
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co.,Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
